{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T20:30:56Z","timestamp":1786653056832,"version":"build-2736575974"},"reference-count":67,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indian J Pharmacol"],"published-print":{"date-parts":[[2015]]},"DOI":"10.4103\/0253-7613.157109","type":"journal-article","created":{"date-parts":[[2015,5,15]],"date-time":"2015-05-15T04:43:34Z","timestamp":1431665014000},"page":"248","source":"Crossref","is-referenced-by-count":7,"title":["Reversing resistance: The next generation antibacterials"],"prefix":"10.4103","volume":"47","author":[{"given":"NeelJayesh","family":"Shah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/0253-7613.157109-1","first-page":"367","volume-title":"Isolation of pre-adaptive mutants in bacteria by sib selection","author":"Cavalli-Sforza","year":"1956","journal-title":"Genetics"},{"key":"key-10.4103\/0253-7613.157109-2","unstructured":"William A, Petri Jr. Penicillins, cephalosporins, and other \u03b2-lactam antibiotics. In: Brunton LL, Chabner BA, Knollmann BC, editors. Goodman and Gilman\u2032s The Pharmacological Basis of Therapeutics. 12 th ed. New York: McGraw-Hill; 2011. p. 1477-503."},{"key":"key-10.4103\/0253-7613.157109-3","unstructured":"McDougall C, Chambers HF. Protein synthesis inhibitors and miscellaneous antibacterial agents. In: Brunton LL, Chabner BA, Knollmann BC, editors. Goodman and Gilman\u2032s The Pharmacological Basis of Therapeutics. 12 th ed. New York: McGraw-Hill; 2011. p. 1521-48."},{"key":"key-10.4103\/0253-7613.157109-4","first-page":"1127","volume-title":"Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus","author":"Higgins","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.4103\/0253-7613.157109-5","first-page":"847","volume-title":"Telavancin for the treatment of hospital-acquired pneumonia: Findings from the ATTAIN studies","author":"Nannini","year":"2012","journal-title":"Expert Rev Anti Infect Ther"},{"key":"key-10.4103\/0253-7613.157109-6","first-page":"859","volume-title":"New lipoglycopeptides: A comparative review of dalbavancin, oritavancin and telavancin","author":"Zhanel","year":"2010","journal-title":"Drugs"},{"key":"key-10.4103\/0253-7613.157109-7","first-page":"3350","volume-title":"Efficacy of oritavancin in a murine model of Bacillus anthracis spore inhalation anthrax","author":"Heine","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.4103\/0253-7613.157109-8","first-page":"2434","volume-title":"Effectiveness of a short (4 day) course of oritavancin in the treatment of simulated Clostridium difficile infection using a human gut model","author":"Chilton","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"key-10.4103\/0253-7613.157109-9","unstructured":"FDA Issues Complete Response Letter for Oritavancin. FierceBiotech. Available from: http:\/\/www.fiercebiotech.com\/press-releases\/fda-issues-complete-response-letter-oritavancin. [Last accessed on 2013 Nov 21]."},{"key":"key-10.4103\/0253-7613.157109-10","unstructured":"The Medicines Company: FDA Accepts Filing of The Medicines Company\u2032s New Drug Application for Intravenous Antibiotic Oritavancin with Priority Review. Available from: http:\/\/www.ir.themedicinescompany.com\/phoenix.zhtml?c=122204 and p=irol newsArticle and ID=1901078 and highlight. [Last accessed on 2014 May 12]."},{"key":"key-10.4103\/0253-7613.157109-11","first-page":"304","volume-title":"Update of dalbavancin spectrum and potency in the USA: Report from the SENTRY Antimicrobial Surveillance Program (2011)","author":"Jones","year":"2013","journal-title":"Diagn Microbiol Infect Dis"},{"key":"key-10.4103\/0253-7613.157109-12","unstructured":"Durata Therapeutics Announces FDA\u2032s Acceptance for Priority Review of NDA for Dalvance (dalbavancin hydrochloride). Available from: http:\/\/www.newdrugapprovals.wordpress.com\/2013\/11\/27\/durata-therapeutics-announces-fdas-acceptance-for-priority-review-of-nda-for-dalvance-dalbavancin-hydrochloride\/. [Last accessed on 2013 Dec 08]."},{"key":"key-10.4103\/0253-7613.157109-13","first-page":"1855","volume-title":"Ertapenem: A review of its use in the management of bacterial infections","author":"Curran","year":"2003","journal-title":"Drugs"},{"key":"key-10.4103\/0253-7613.157109-14","unstructured":"Drug Approval Package: Doribax (Doripenem) NDA #022106. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2007\/022106s000_LBL.pdf. [Last accessed on 2014 Jan 13]."},{"key":"key-10.4103\/0253-7613.157109-15","first-page":"511","volume-title":"Multicenter randomized controlled trial on combination therapy with 0.1% adapalene gel and oral antibiotics for acne vulgaris: Comparison of the efficacy of adapalene gel alone and in combination with oral faropenem","author":"Hayashi","year":"2012","journal-title":"J Dermatol"},{"key":"key-10.4103\/0253-7613.157109-16","first-page":"2427","volume-title":"TAK-599, a novel N-phosphono type prodrug of anti-MRSA cephalosporin T-91825: Synthesis, physicochemical and pharmacological properties","author":"Ishikawa","year":"2003","journal-title":"Bioorg Med Chem"},{"key":"key-10.4103\/0253-7613.157109-17","first-page":"809","volume-title":"Ceftaroline: A novel broad-spectrum cephalosporin with activity against meticillin-resistant Staphylococcus aureus","author":"Zhanel","year":"2009","journal-title":"Drugs"},{"key":"key-10.4103\/0253-7613.157109-18","first-page":"6358","volume-title":"Activity of ceftaroline against Enterococcus faecium PBP5","author":"Henry","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.4103\/0253-7613.157109-19","first-page":"5600","volume-title":"In vitro activity of ceftaroline-avibactam against gram-negative and gram-positive pathogens isolated from patients in Canadian hospitals from 2010 to 2012: Results from the CANWARD surveillance study","author":"Karlowsky","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.4103\/0253-7613.157109-20","first-page":"758","volume-title":"High incidence of discontinuations due to adverse events in patients treated with ceftaroline","author":"Jain","year":"2014","journal-title":"Pharmacotherapy"},{"key":"key-10.4103\/0253-7613.157109-21","first-page":"240","volume-title":"A randomised, double-blind trial comparing ceftobiprole medocaril with ceftriaxone with or without linezolid for the treatment of patients with community-acquired pneumonia requiring hospitalisation","author":"Nicholson","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"key-10.4103\/0253-7613.157109-22","unstructured":"Deck DH, Winston LG. Beta-lactam and other cell wall- and membrane-active antibiotics. In: Katzung BG, Masters SB, Trevor AJ, editors. Basic and Clinical Pharmacology. 12 th ed. New York, London: McGraw-Hill; 2012. p. 805."},{"key":"key-10.4103\/0253-7613.157109-23","doi-asserted-by":"crossref","unstructured":"Scorciapino MA, Rinaldi AC. Antimicrobial peptidomimetics: Reinterpreting nature to deliver innovative therapeutics. Front Immunol 2012;3:171. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3394240\/. [Last accessed on 2013 Dec 10].","DOI":"10.3389\/fimmu.2012.00171"},{"key":"key-10.4103\/0253-7613.157109-24","first-page":"1010","volume-title":"Peptidomimetic antibiotics target outer-membrane biogenesis in Pseudomonas aeruginosa","author":"Srinivas","year":"2010","journal-title":"Science"},{"key":"key-10.4103\/0253-7613.157109-25","unstructured":"Polyphor - Antibiotic POL7080. Available from: http:\/\/www.polyphor.com\/products\/pol7080. [Last accessed on 2013 Dec 10]."},{"key":"key-10.4103\/0253-7613.157109-26","first-page":"78","volume-title":"Peptidoglycan glycosyltransferase substrate mimics as templates for the design of new antibacterial drugs","author":"Derouaux","year":"2013","journal-title":"Front Immunol"},{"key":"key-10.4103\/0253-7613.157109-27","first-page":"175","volume-title":"Antimicrobial growth promoters used in animal feed: Effects of less well known antibiotics on gram-positive bacteria","author":"Butaye","year":"2003","journal-title":"Clin Microbiol Rev"},{"key":"key-10.4103\/0253-7613.157109-28","first-page":"743","volume-title":"Meonomycin, a new antibiotic 3.Biological properties","author":"von","year":"1965","journal-title":"Antimicrob Agents Chemother (Bethesda)"},{"key":"key-10.4103\/0253-7613.157109-29","first-page":"4610","volume-title":"Syntheses around the transglycosylation step in peptidoglycan biosynthesis","author":"Welzel","year":"2005","journal-title":"Chem Rev"},{"key":"key-10.4103\/0253-7613.157109-30","first-page":"649","volume-title":"Contrasting effects of acidic pH on the extracellular and intracellular activities of the anti-gram-positive fluoroquinolones moxifloxacin and delafloxacin against Staphylococcus aureus","author":"Lemaire","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.4103\/0253-7613.157109-31","first-page":"259","volume-title":"Treatment of infections due to resistant Staphylococcus aureus","author":"Anstead","year":"2014","journal-title":"Methods Mol Biol"},{"key":"key-10.4103\/0253-7613.157109-32","unstructured":"A Study to Assess Objective Endpoint Measurements of Response in Bacterial Skin Infections-Study Results-ClinicalTrials.gov. Available from: http:\/\/www.clinicaltrials.gov\/ct2\/show\/results\/NCT01283581?term=delafloxacin and rank=3 and sect=X6015#outcome1. [Last accessed on 2013 Dec 12]."},{"key":"key-10.4103\/0253-7613.157109-33","first-page":"2411","volume-title":"In vivo antibacterial activity of nemonoxacin, a novel non-fluorinated quinolone","author":"Li","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"key-10.4103\/0253-7613.157109-34","unstructured":"HHS (U.S. Department of Health and Human Services) Forms Strategic Alliance to Develop New Antibiotics. Available from: http:\/\/www.phe.gov\/Preparedness\/news\/Pages\/strategic-alliance-130522.aspx. [Last accessed on 2013 Dec 12]."},{"key":"key-10.4103\/0253-7613.157109-35","doi-asserted-by":"crossref","unstructured":"Clay KD, Hanson JS, Pope SD, Rissmiller RW, Purdum PP 3 rd , Banks PM. Brief communication: Severe hepatotoxicity of telithromycin: Three case reports and literature review. Ann Intern Med 2006;144:415-20.","DOI":"10.7326\/0003-4819-144-6-200503210-00121"},{"key":"key-10.4103\/0253-7613.157109-36","first-page":"537","volume-title":"Antimicrobial characterisation of CEM-101 activity against respiratory tract pathogens, including multidrug-resistant pneumococcal serogroup 19A isolates","author":"Farrell","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"key-10.4103\/0253-7613.157109-37","first-page":"2526","volume-title":"Randomized, double-blind, multicenter phase 2 study comparing the efficacy and safety of oral solithromycin (CEM-101) to those of oral levofloxacin in the treatment of patients with community-acquired bacterial pneumonia","author":"Oldach","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.4103\/0253-7613.157109-38","first-page":"76","volume-title":"A novel macrolide solithromycin exerts superior anti-inflammatory effect via NF-kB inhibition","author":"Kobayashi","year":"2013","journal-title":"J Pharmacol Exp Ther"},{"key":"key-10.4103\/0253-7613.157109-39","first-page":"447","volume-title":"Maternal administration of solithromycin, a new, potent, broad-spectrum fluoroketolide antibiotic, achieves fetal and intra-amniotic antimicrobial protection in a pregnant sheep model","author":"Keelan","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.4103\/0253-7613.157109-40","first-page":"1279","volume-title":"Mechanism of action of the novel aminomethylcycline antibiotic omadacycline","author":"Draper","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.4103\/0253-7613.157109-41","first-page":"1847","volume-title":"Phase 2, randomized, double-blind study of the efficacy and safety of two dose regimens of eravacycline versus ertapenem for adult community-acquired complicated intra-abdominal infections","author":"Solomkin","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.4103\/0253-7613.157109-42","unstructured":"FDA Grants QIDP Designation to Eravacycline, Tetraphase\u2032s Lead Antibiotic Product Candidate. Available from: http:\/\/www.fdanews.com\/articles\/157074-fda-grants-qidp-designation-to-eravacycline-tetraphase-s-lead-antibiotic-product-candidate. [Last accessed on 2013 Dec 13]."},{"key":"key-10.4103\/0253-7613.157109-43","first-page":"346","volume-title":"The aminoglycoside resistance methyltransferases from the ArmA\/Rmt family operate late in the 30S ribosomal biogenesis pathway","author":"Zarubica","year":"2011","journal-title":"RNA"},{"key":"key-10.4103\/0253-7613.157109-44","first-page":"191","volume-title":"Activity of plazomicin (ACHN-490) against MDR clinical isolates of Klebsiella pneumoniae, Escherichia coli, and Enterobacter spp.from Athens, Greece","author":"Galani","year":"2012","journal-title":"J Chemother"},{"key":"key-10.4103\/0253-7613.157109-45","first-page":"2554","volume-title":"In vitro activity of plazomicin against 5,015 gram-negative and gram-positive clinical isolates obtained from patients in Canadian hospitals as part of the CANWARD study, 2011-2012","author":"Walkty","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.4103\/0253-7613.157109-46","unstructured":"Cubist Announces Submission of New Drug Application for Investigational Antibiotic Tedizolid for Treatment of Serious Skin Infections. Available from: http:\/\/www.cubist.com\/news\/111-cubist_announces_submission_of_new_drug_application_for_investigational_antibiotic_tedizolid_for_treatment_of_serious_skin_infections. [Last accessed on 2013 Dec 14]."},{"key":"key-10.4103\/0253-7613.157109-47","unstructured":"FDA Advisory Committee Unanimously Recommends Approval of Cubist\u2032s SIVEXTRO TM (Tedizolid Phosphate) as Treatment for Serious Skin Infections. Available from: http:\/\/www.cubist.com\/news\/129-fda_advisory_committee_unanimously_recommends_approval_of_cubists_sivextrotm_tedizolid_phosphate_as_treatment_for_serious_skin_infections. [Last accessed on 2014 May 12]."},{"key":"key-10.4103\/0253-7613.157109-48","first-page":"2540","volume-title":"Cellular pharmacokinetics of the novel biaryloxazolidinone radezolid in phagocytic cells: Studies with macrophages and polymorphonuclear neutrophils","author":"Lemaire","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.4103\/0253-7613.157109-49","first-page":"4442","volume-title":"In vitro activity of TR-700, the antibacterial moiety of the prodrug TR-701, against linezolid-resistant strains","author":"Shaw","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.4103\/0253-7613.157109-50","first-page":"4494","volume-title":"Daptomycin-mediated reorganization of membrane architecture causes mislocalization of essential cell division proteins","author":"Pogliano","year":"2012","journal-title":"J Bacteriol"},{"key":"key-10.4103\/0253-7613.157109-51","first-page":"4255","volume-title":"Bactericidal action of daptomycin against stationary-phase and nondividing Staphylococcus aureus cells","author":"Mascio","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.4103\/0253-7613.157109-52","first-page":"1860","volume-title":"Muscle pain associated with daptomycin","author":"Veligandla","year":"2004","journal-title":"Ann Pharmacother"},{"key":"key-10.4103\/0253-7613.157109-53","first-page":"1759","volume-title":"An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site","author":"Rock","year":"2007","journal-title":"Science"},{"key":"key-10.4103\/0253-7613.157109-54","unstructured":"GSK Exercises Option on Anacor\u2032s Novel Antibiotic for the Treatment of Gram-Negative Infections. Available from: http:\/\/www.us.gsk.com\/html\/media-news\/pressreleases\/2010\/2010_pressrelease_10081.htm. [Last accessed on 2013 Dec 28]."},{"key":"key-10.4103\/0253-7613.157109-55","unstructured":"Search of: GSK1322322-List Results-ClinicalTrials.gov. Available from: http:\/\/www.clinicaltrials.gov\/ct2\/results?term=GSK1322322 and Search=Search. [Last accessed on 2013 Dec 31]."},{"key":"key-10.4103\/0253-7613.157109-56","first-page":"2333","volume-title":"Comparative analysis of the antibacterial activity of a novel peptide deformylase inhibitor, GSK1322322","author":"O\u2032Dwyer","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.4103\/0253-7613.157109-57","first-page":"1256","volume-title":"Actinonin, a naturally occurring antibacterial agent, is a potent deformylase inhibitor","author":"Chen","year":"2000","journal-title":"Biochemistry"},{"key":"key-10.4103\/0253-7613.157109-58","first-page":"1580","volume-title":"In vitro activity of API-1252, a novel FabI inhibitor, against clinical isolates of Staphylococcus aureus and Staphylococcus epidermidis","author":"Karlowsky","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.4103\/0253-7613.157109-59","first-page":"39285","volume-title":"Structure of acyl carrier protein bound to FabI, the FASII enoyl reductase from Escherichia coli","author":"Rafi","year":"2006","journal-title":"J Biol Chem"},{"key":"key-10.4103\/0253-7613.157109-60","unstructured":"Anti-infective Drugs Advisory Committee Meeting Briefing Document TMC207 (bedaquiline). Available from: http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/Anti-InfectiveDrugsAdvisoryCommittee\/UCM329260.pdf. [Last accessed on 2014 Jan 14]."},{"key":"key-10.4103\/0253-7613.157109-61","first-page":"2151","volume-title":"Delamanid for multidrug-resistant pulmonary tuberculosis","author":"Gler","year":"2012","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0253-7613.157109-62","unstructured":"Deltyba Approved for Multidrug-Resistant TB in Europe. Available from: http:\/\/www.medscape.com\/viewarticle\/824468. [Last accessed on 2014 May 18]."},{"key":"key-10.4103\/0253-7613.157109-63","first-page":"86","volume-title":"In vitro activity of avibactam (NXL104) in combination with \u00df-lactams against Gram-negative bacteria, including OXA-48 \u00df-lactamase-producing Klebsiella pneumoniae","author":"Aktas","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"key-10.4103\/0253-7613.157109-64","unstructured":"IDSA\u202f: Antibiotic Development: The 10 \u00d7 \u203220 Initiative. Available from: http:\/\/www.idsociety.org\/10 \u00d7 20\/. [Last accessed on 2013 Nov 07]."},{"key":"key-10.4103\/0253-7613.157109-65","unstructured":"Commissioner of the Food and Drug Administration Safety and Innovation Act (FDASIA). Available from: http:\/\/www.fda.gov\/RegulatoryInformation\/Legislation\/FederalFoodDrugandCosmeticActFDCAct\/SignificantAmendmentstotheFDCAct\/FDASIA\/ucm20027187.htm. [Last accessed on 2013 Nov 07]."},{"key":"key-10.4103\/0253-7613.157109-66","doi-asserted-by":"crossref","unstructured":"Farrington M. Chemotherapy of infections. In: Bennett PN, Brown MJ, Sharma PJ, editors. Clinical Pharmacology. 11 th ed. Edinburgh, New York: Elsevier; 2012. p. 162-72.","DOI":"10.1016\/B978-0-7020-4084-9.00051-3"},{"key":"key-10.4103\/0253-7613.157109-67","first-page":"1959","volume-title":"Return of chloroquine antimalarial efficacy in Malawi","author":"Laufer","year":"2006","journal-title":"N Engl J Med"}],"container-title":["Indian Journal of Pharmacology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:30:41Z","timestamp":1786649441000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/0253-7613.157109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":67,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015]]}},"alternative-id":["157109"],"URL":"https:\/\/doi.org\/10.4103\/0253-7613.157109","relation":{},"ISSN":["0253-7613"],"issn-type":[{"value":"0253-7613","type":"print"}],"subject":[],"published":{"date-parts":[[2015]]}}}